The Stock is Insanely Under Valued It is intere
Post# of 9144
Posted On: 09/02/2014 2:46:15 PM
The Stock is Insanely Under Valued
It is interesting to see no trades today and not many the other day. But it is also easy to see that the NanoLogix shares are incredibly undervalued and that to sell at this price is throwing money away. I want to do some more specific work on the implications/possibilities of three areas. They are:
1. The Hospital Acquired Infections (HAI) situation in which there is a problem between insurance companies' push to get patients released as fast as possible and the Medicare Center's expanding policy on not paying for infections that the hospital didn't detect quickly enough to treat prior to release;
2. The potential scope and frequency of lawsuits and so forth based on hospital and doctor failures to rapidly and accurately diagnose things like MRSA and sepsis since those bacterial diseases clearly still cause a great deal of illness and death; and
3. The scope of bacterial concerns commonly associated with veterinarians' treatment of animals. The idea is that it might be possible to design an N-Assay panel for those diagnoses and if so it could become a significant revenue enhancer for vet practices that at the moment have to ship most of this stuff out to labs. With a machine readable system they might be able to test in-house and create an expanded revenue stream. Since vet practices don't have the luxury of health insurance for pets like people hospitals and doctors they could be open to a technology that keeps money in the practice. And there are many, many vet offices.
It is interesting to see no trades today and not many the other day. But it is also easy to see that the NanoLogix shares are incredibly undervalued and that to sell at this price is throwing money away. I want to do some more specific work on the implications/possibilities of three areas. They are:
1. The Hospital Acquired Infections (HAI) situation in which there is a problem between insurance companies' push to get patients released as fast as possible and the Medicare Center's expanding policy on not paying for infections that the hospital didn't detect quickly enough to treat prior to release;
2. The potential scope and frequency of lawsuits and so forth based on hospital and doctor failures to rapidly and accurately diagnose things like MRSA and sepsis since those bacterial diseases clearly still cause a great deal of illness and death; and
3. The scope of bacterial concerns commonly associated with veterinarians' treatment of animals. The idea is that it might be possible to design an N-Assay panel for those diagnoses and if so it could become a significant revenue enhancer for vet practices that at the moment have to ship most of this stuff out to labs. With a machine readable system they might be able to test in-house and create an expanded revenue stream. Since vet practices don't have the luxury of health insurance for pets like people hospitals and doctors they could be open to a technology that keeps money in the practice. And there are many, many vet offices.
(0)
(0)